Bristol-Myers Squibb BMY Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's deferred tax assets and other non-current assets?
- Bristol-Myers Squibb (BMY) reported deferred tax assets and other non-current assets of $6.08B in Q1 2026.
- How has Bristol-Myers Squibb's deferred tax assets and other non-current assets changed year-over-year?
- Bristol-Myers Squibb's deferred tax assets and other non-current assets increased by 3.7% year-over-year, from $5.87B to $6.08B.
- What is the long-term trend for Bristol-Myers Squibb's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's deferred tax assets and other non-current assets has grown at a -1.6% compound annual growth rate (CAGR), from $7.02B to $6.47B.